Tuesday Aug 19
Report Published: "Itero Biopharmaceuticals, Inc. - Pharmaceuticals & ...
The company develops, manufactures and commercializes protein therapeutics. It develops and commercializes recombinant DNA-produced medicines which include monoclonal antibodies.
Customer Interaction Solutions
Actavis PLC - 10-Q - Management's Discussion and Analysis of...
The following discussion of our financial condition and the results of operations should be read in conjunction with the "Consolidated Financial Statements" and notes thereto included elsewhere in this Quarterly Report on Form 10-Q and our audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended ... (more)
Investor's Business Daily
Actavis Fuels Growth With Acquisitions, New Generics
Since closing its acquisition of Forest Laboratories on July 2, when new CEO Brenton Saunders took the helm, Actavis has completed a $1.1 billion purchase of Furiex Pharmaceuticals, and confirmed it filed patent challenges for generic versions of two drugs.